Background
==========

The cytochromes P450 (CYPs) played an important role in the development of various cancers, since they involved in the metabolic transformation of numerous endogenous and exogenous compounds including carcinogens and anti-cancer drugs \[[@B1]\]. Cytochrome P450 1A2 (CYP1A2), as one of important CYP enzymes, is responsible for the metabolic activation of pro-carcinogens such as heterocyclic aromatic amines (HAA), polycyclic aromatic hydrocarbons (PAHs) and 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) and further contributes to the risk of cancer \[[@B2],[@B3]\].

*CYP1A2* gene has been mapped on chromosome 15q24.1 and head to head shares a bidirectional promoter with *CYP1A1* gene \[[@B4]\]. It has been demonstrated that the expression of *CYP1A2* existed large inter-individual variability in the liver \[[@B5]\] and it is believed that the expression of *CYP1A2* is regulated by constitutive expression and inducible expression from environmental chemicals \[[@B3],[@B6]\].

*CYP1A2* is highly polymorphic and there are more than 200 polymorphisms existed in *CYP1A2* gene region according to NCBI dbSNP database ( <http://www.ncbi.nlm.nih.gov>) and SNP500Cancer ( <http://variatgps.nci.nih.gov>). Previous studies have extensively focused on *CYP1A2* -164A\>C polymorphism (*CYP1A2*\*1F; rs762551) \[[@B7],[@B8]\], which is located in the intron1 of *CYP1A2*. There also have several reported studied three common variations, that is -3860G\>A polymorphism (*CYP1A2*\*1C; rs2069514) \[[@B8],[@B9]\], -739G\>T polymorphism (rs2069526) \[[@B8],[@B10]\] and 1545T\>C polymorphism (rs2470890) \[[@B10],[@B11]\]. These polymorphisms may be related to altered inducibility of CYP1A2 expression by environmental chemicals and consequently influence the individual susceptibility to certain cancer. For example, the *CYP1A2* rs2069514 A allele has been demonstrated to associated with decreased enzyme activity in smokers and *CYP1A2* rs762551 polymorphism is also associated with altered expression of *CYP1A2* by cigarette smoking \[[@B12]-[@B14]\].

Recently, many studies have investigated the association of *CYP1A2* polymorphisms and the risk of various cancers, including lung cancer, breast cancer, colorectal cancer, stomach cancer and others in various populations \[[@B15]-[@B18]\]. However, the results of these studies are not consistent and inconclusive. Considering the role of CYP1A2 in defending against environmental carcinogens and in the development of cancers, we performed a systematic meta-analysis from all eligible studies to address the overall risk of *CYP1A2* variants in the development of all cancers involved.

Methods
=======

Identification and eligibility of relevant studies
--------------------------------------------------

Remote PubMed, Embase, OVID, ScienceDirect, and Chinese National Knowledge Infrastructure database (between January 2003 and December 2011) was searched using the search terms: CYP1A2/P4501A2/phase II enzymes, polymorphism/polymorphisms/genotype and cancer/carcinoma/adenomas to identify all publications, which investigated the association of the *CYP1A2* polymorphism with cancer risk in all ethnic populations. We evaluated the titles and abstracts of all relevant papers, but excluded case reports, editorials and reviews. All publications in English language with available full text matching the eligible criteria were retrieved. For inclusion in this meta-analysis, the identified articles had to provide information on the following: (1) using a case--control design, (2) sufficient data for examining an odds ratio (OR) with 95% confidence interval (CI) and (3) was a study of the *CYP1A2* rs762551 polymorphism and cancer risk, (4) genotype distributions of polymorphism are consistent with hardy-Weinberg Equilibrium (HWE). In addition, we checked the references of relevant reviews and eligible articles that our search retrieved by two investigators independently.

Methods for quantitative analysis
---------------------------------

We examined the association between *CYP1A2* rs762551 A\>C polymorphism and the risk of cancer by calculating pooled odds ratio (ORs) and 95% confidence intervals (CI) in genetic model of CC versus AA, dominant model (CC+CA versus AA) and recessive model (CC versus CA+AA). The significance of pooled OR was tested by Z test. The *χ*2-based Q-test was also used to examine the heterogeneity assumption \[[@B19]\]. If studies' findings only differ by the sampling (*P*≥0.05), a fixed-effects model could be used to calculate the combined OR. By contrast, if the *P* value of the Q tests is below 0.05, which showed that the study results statistically differ by heterogeneous case and sampling, a random-effects model could be more suitable. Since we used accumulating data from a series of studies, which had been conducted by researchers operating independently, the random model was more easily justified than the fixed model \[[@B20],[@B21]\]. The summary OR and 95% CI were calculated under the random effect model.

The leave-one-out sensitivity analysis was conducted to determine whether our assumptions or decisions have a major effect on the results of the review by omitting each study (one at a time) \[[@B22]\]. Furthermore, subgroup analyses were performed to test whether the effect size varied by the ethnicity and the source of control population. To evaluate the published bias, we used funnel plot analysis, which is graphical display of sample size plotted against effect size for the studies included in a meta-analysis \[[@B23]\]. To test for funnel plot asymmetry, Egger's test was performed \[[@B24]\]. All of calculations were performed using R program.

Results
=======

Characteristics of meta-analyses database
-----------------------------------------

After preliminary screening as of 15 December 2011, there were 53 relevant publications fitting the key terms. We excluded 34 studies by (1) no related *CYP1A2* polymorphism, (2) no cancer case--control design, (3) review articles \[[@B25],[@B26]\], (4) no usable genotype data \[[@B27]-[@B30]\] and included 19 studies \[[@B7]-[@B11],[@B16]-[@B18],[@B31]-[@B41]\] in this meta-analysis (Figure [1](#F1){ref-type="fig"} and Table [1](#T1){ref-type="table"}). Overall, the studies involved in 8,218 cases and 11,165 controls. The genotype distributions for *CYP1A2* rs762551 polymorphism are shown in Table [2](#T2){ref-type="table"}.
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###### 

Characteristics of the studies included in the meta-analysis

  **Author**                **Year**   **Country**   **Ethnicity**   **Cancer type**   **Cases**   **Controls**   **Source of controls**   **Genotype method**
  ------------------------- ---------- ------------- --------------- ----------------- ----------- -------------- ------------------------ ---------------------
  Khvostova \[[@B7]\]       2011       Russia        Caucasian       Breast            323         526            Hospital                 PCR-RFLP
  MARIE-GENICA \[[@B31]\]   2010       German        Caucasian       Breast            3147        5485           Population               PCR-RFLP
  Singh \[[@B8]\]           2010       India         Asian           Lung              200         200            Population               PCR-RFLP
  Sangrajrang \[[@B16]\]    2009       Thailand      Asian           Breast            552         483            Hospital                 TaqMan
  B′chir \[[@B9]\]          2009       Tunisia       Tunisian        Lung              101         98             Hospital                 PCR-RFLP
  Kobayashi \[[@B17]\]      2009       Japan         Asian           Stomach           141         286            Hospital                 MassARRAY
  Altayli \[[@B32]\]        2009       Turkey        Caucasian       Bladder           135         128            Hospital                 PCR-RFLP
  Aldrich \[[@B33]\]        2009       USA           Mixed           Lung              113         299            Mixed                    Not defined
  Saebo \[[@B35]\]          2008       Norway        Caucasian       Colorectal        198         222            Hospital                 PCR-RFLP
  Suziki \[[@B34]\]         2008       USA           Caucasian       Pancreatic        649         585            Population               PCR-RFLP
  Yoshida \[[@B36]\]        2007       Japan         Asian           Colorectal        64          111            Hospital                 PCR-RFLP
  Osawa \[[@B18]\]          2007       Japan         Asian           Lung              103         111            Hospital                 PCR-RFLP
  Gemignani \[[@B10]\]      2007       Italy         Caucasian       Lung              297         310            Hospital                 Microarray
  Kotsopoulos \[[@B37]\]    2007       Canada        Caucasian       Breast            170         241            Hospital                 PCR-RFLP
  Bae \[[@B40]\]            2006       Korea         Asian           Colorectal        111         93             Hospital                 PCR-RFLP
  Long \[[@B38]\]           2006       China         Asian           Breast            1082        1139           Population               PCR-RFLP
  Li \[[@B39]\]             2006       USA           Caucasian       Pancreatic        307         333            Population               PCR-RFLP
  Landi \[[@B11]\]          2005       spain         Caucasian       Colorectal        361         321            Hospital                 APEX
  Goodman \[[@B41]\]        2003       USA           Caucasian       Ovarian           164         194            Population               PCR-RFLP

*PCR*, polymerase chain reaction; *RFLP*, restriction fragment length polymorphis; *APEX*, arrayed primer exension.

###### 

CYP1A2 rs762551 polymorphism and cancer risk stratified by characteristics of studies

  **Variables**         **Genotype of rs762551 (Cases/Controls)**   **CC vs AA**   **Dominant model (CC+CA vs AA)**   **Recessive model (CC vs CA+AA)**                                          
  -------------------- ------------------------------------------- -------------- ---------------------------------- ----------------------------------- ------------------- ------------------- -------------------
  All                                  8218/11165                    3750/5374                3567/4720                           901/1071                1.30(1.02-1.64)\*   1.19(1.04-1.36)\*    1.19(0.99-1.44)
  Cancer site                                                                                                                                                                                              
   Lung                                 814/1018                      277/426                  380/443                             157/149                 1.27(0.63-2.61)     1.09(0.63-1.89)     1.27(0.82-1.95)
   Colorectal                            734/747                      288/366                  362/310                              84/71                  1.50(0.96-2.33)     1.52(0.95-2.42)     1.15(0.73-1.81)
   Breast                               5274/7874                    2544/3848                2204/3331                            526/695                 1.44(0.82-2.55)     1.07(0.93-1.24)     1.15(0.73-1.81)
   Other                                1396/1526                     641/734                  621/636                             134/156                 1.04(0.79-1328)     1.12(0.96-1.31)     0.97(0.73-1.30)
  Ethnicity                                                                                                                                                                                                
   Caucasian                            5751/8345                    2804/4199                2417/3463                            530/683                1.29(1.27-1.63)\*   1.17(1.02-1.34)\*    1.19(0.98-1.45)
   Asian                                2253/2423                     867/989                 1055/1086                            331/348                 1.27(0.83-1.93)     1.24(0.93-1.66)     1.10(0.76-1.59)
   Mixed                                 214/397                       79/186                   95/171                              40/40                 1.34(0.14-12.95)     0.87(0.17-4.40)     1.68(0.44-6.35)
  Source of Controls                                                                                                                                                                                       
   Population                           5549/7936                    2590/3777                2388/3387                            571/772                 1.01(0.89-1.14)     1.02(0.92-1.14)     1.00(0.89-1.13)
   Hospital                             2556/2930                    1114/1426                1128/1219                            314/285                 1.35(0.97-1.88)     1.21(0.98-1.50)     1.26(0.96-1.65)
   Other                                 113/299                       46/171                   51/114                              16/14                 4.25(1.93-9.34)\*   1.95(1.25-3.02)\*   3.36(1.58-7.13)\*

\* *P*\<0.05.

The characteristics of populations and cancer types of final 19 publications were listed in Table [1](#T1){ref-type="table"}. This meta-analysis involved in 5 breast cancer studies, 5 lung cancer studies, 4 colorectal cancer studies and 5 studies with other cancer types. Of these, there were 10 studies conducted in Caucasian, 7 studies in Asian, 1 study in Tunisian, and 1 study included multiple ethnicities. There were 6 population-based studies, 12 hospital-based studies, and 1 study with mixed controls study. Variant genotyping methods were used, which included polymerase chain reaction restriction fragment length polymorphism assay (PCR-RFLP) in 14 studies, TaqMan assay, MassARRAY, microarray, arrayed primer extension (APEX) and unknown method in one study each. Overall, the genotyping frequencies of *CYP1A2* rs762551 polymorphism were in agreement with the Hardy-Weinberg equilibrium in both cases and controls.

Quantitative synthesis
----------------------

Regarding *CYP1A2* rs762551 polymorphism, the eligible studies involved in 8218 cases and 11165 controls. For each study, we investigated the association based on the assumption of different inheritance models of *CYP1A2* rs762551 A\>C polymorphism. In all inheritance models of rs762551 polymorphism, due to the between-study heterogeneity in the individual studies (all *P* for Q test \< 0.01 and I^2^\>25%), the random-effect model was used to analyze the data \[[@B42]\]. We identified that rs762551 polymorphism had a weak correlation with the risk of cancer (CC versus AA, OR = 1.30, 95% CI = 1.02-1.64; dominant model, OR = 1.19, 95% CI = 1.04-1.36), but not in recessive model (OR = 1.19, 95% CI = 0.99-1.44) (Figure [2](#F2){ref-type="fig"} and Table [2](#T2){ref-type="table"}).
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Several subgroup analyses were also performed according to the population ethnicity, cancer type, or source of control population (Table [2](#T2){ref-type="table"}). When we analyzed the relationship of rs762551 polymorphism and cancer risk in different ethnicity subgroup. Our data showed that rs762551 A\>C polymorphism increased the cancer risk (CC versus AA, OR = 1.29, 95% CI = 1.27-1.63; dominant model, OR = 1.17, 95% CI = 1.02-1.34) in Caucasians, but not in Asians (CC versus AA, OR = 1.27, 95% CI = 0.83-1.93; dominant model, OR = 1.24, 95% CI = 0.93-1.66) and in other mixed population (CC versus AA, OR = 1.34, 95% CI = 0.14-12.95; dominant model, OR = 0.87, 95% CI = 0.17-4.40). In recessive genetic model, our study didn't show any significant correlation between rs762551 polymorphism and the cancer risk with OR (95% CI) of 1.19 (0.98-1.45), 1.10 (0.76-1.59) and 1.68 (0.44-6.35) in Caucasians, Asians and other mixed population, respectively (Figure [2](#F2){ref-type="fig"} and Table [2](#T2){ref-type="table"}). We didn't observe any significant association among other subgroups (cancer type and source of control) subgroup in any genetic model using random effect model (Table [2](#T2){ref-type="table"}).

Sensitivity analysis
--------------------

In order to compare the sensitivity of the meta-analysis, we conducted a leave-one-out sensitivity analysis (Additional file [1](#S1){ref-type="supplementary-material"}: Table S1). A single study involved in this meta-analysis was evaluated each time to reflect the influence of the individual data set to pooled ORs. The results pattern was not impacted by single study in all genetic models. The *P* for Q test and the I^2^ value also showed that none of single study affected the heterogeneity of this meta-analysis.

Statistical uncertainty of finding
----------------------------------

For risk assessment, statistical uncertainty is associated with the model selected \[[@B43]\]. In this meta-analysis, we evaluated the association of *CYP1A2* rs762551 polymorphism with cancer risk in different genetic models (CC versus AA model, dominant model and recessive model). The results showed the difference among these genetic models. We found the rs672551 polymorphism was associated with cancer risk under CC versus AA model and dominant model, but not under recessive model.

Bias diagnostics
----------------

To evaluate the publication bias of rs762551 variant in the overall meta-analysis, the funnel plot and Egger's test were used. In this analysis, the funnel plot showed a relatively symmetric distribution (Figure [3](#F3){ref-type="fig"}), but the point cloud didn't have a distinctive form. No publication bias was detected by the Egger's test (*t* = 1.4870, *P* = 0.1553). However, the deficient funnel form of the funnel plot could be due to the relatively high heterogeneity with respect to the different ethnicity and the source of control population. Furthermore, the number of studies was relatively small and the publication bias may still exist.

![**Funnel plot analysis to detect publication bias for rs762551 polymorphism (CC versus AA).** Each point represents an individual study for the indicated association.](1471-2407-12-528-3){#F3}

Discussion
==========

Various studies provided evidences that genetics play an important role in determining cancer risk and association studies have been identified to evaluate cancer susceptibility \[[@B44]\]. However, many association studies failed to provide convincing evidence of linkage and have resulted in contradicting findings, especially in small sample sizes \[[@B45]\]. Meta-analysis provided a popular method for combining world literatures across studies to resolve the statistical power and discrepancy problem in associate studies \[[@B46]\]. Based on 19 studies providing data on *CYP1A2* rs762551 polymorphism and cancer risk, we conduced a meta-analysis involving in 8218 cancer cases and 11165 controls to indicate if the rs762551 polymorphism was significantly associated with risk of cancer. We evaluated the publication bias. The *CYP1A2* rs762551 A\>C genotypes funnel plot was approximately symmetrical and the Eggle's test showed that there is no publication bias in the study of *CYP1A2* rs762551 (*P* = 0.1553). We found that the carriers of *CYP1A2* rs762551 C allele had a weak effect on the overall cancer risk in allele genetic model and in the dominant genetic model. These results suggested that the *CYP1A2* rs762551 polymorphism might be useful for assessing cancer risk.

CYP1A2 is a critical enzyme involved in drug metabolism and carcinogen bioactivation. The expression and activity of CYP1A2 has been demonstrated to relate to the risk of various cancers \[[@B2],[@B6],[@B41],[@B47]\]. *CYP1A2* gene is genetically polymorphic in human. To date, 177 SNPs have been deposited in the NCBI database and the frequency of these SNPs varies by ethnicity. Many of these SNPs are in linkage disequilibrium and a few SNPs have been reported to be functional \[[@B14],[@B48]\]. For example, *CYP1A2*\*1F (rs762551) polymorphism can result in 2--3 fold increase in activity/protein and has been associated with inducibility \[[@B49]\]. Our current analysis showed that the CC genotype of rs762551 elevated the individual susceptibility to the cancer risk. This is consistent to the function of *CYP1A2* rs762551 polymorphism. However, we didn't observe any correction of CC genotype with the cancer risk in subgroup analysis by cancer type. This biochemical mechanism was still unclear. In addition, due to the low OR in our study, our results should be interpreted cautiously. The *CYP1A2* polymorphism may prove to be useful for assessing cancer risk.

It has been well known that cancer occurrence and mortality varied by ethnicity and geographic location \[[@B50]\]. In this meta-analysis, all subjects were subgrouped into three groups (Caucasian, Asian and other populations). No association of rs762551 polymorphism with cancer risk was detected in Asian and mixed population, while increased cancer risk was demonstrated in Caucasians. This finding reflected the difference of cancer susceptibility in different ethnicity, due to different genetic background and environmental exposure. However due to the low OR in this meta-analysis, further investigation still need to be conducted in a large scale Asian population.

Any meta-analysis has it limitations. To better interpreting the finding, several limitations need to be considered in current analysis. Firstly, potential publication biases may exist in this meta-analysis because studies excluded the non-English-language publications. Secondly, the total study size was still too small to perform subgroup analysis. Thirdly, this meta-analysis was based on unadjusted data due to a lack of detailed genotype information stratified by main confounding variables, such as gender, age, smoking status in original articles.

Conclusions
===========

In summary, our meta-analysis demonstrated a weak association of *CYP1A2* rs762551 polymorphism with cancer risk, mainly in Caucasian population. However, as a potentially powerful tool for assessing population effects of genetic variants, meta-analysis cannot replace for adequate genetic association studies. Also, to reach a more definitive conclusion, further gene-gene interaction and gene-environment interaction studies, which based on large sample size, are still needed in different population.
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